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Abstract
Background: Epithelial ovarian cancer survivors (EOCSs) frequently report multiple complaints
after their treatment. The objective was to study somatic and mental morbidity in EOCSs
associated with their Self- Rated Health (SRH) assessed by a single item.
Findings were compared to age-matched controls from the general population.
Methods: In a cross -sectional follow-up design 189/287 (66%) EOCSs treated at The Norwegian
Radiumhospital 1979–2003 responded to a mailed questionnaire on demographic data, and somatic
and mental morbidity. SRH last week was rated on item #29 of the European Organization and
Treatment of Cancer Quality of Life Questionnaire in 84/189 (97%) of responding EOCSs. For
comparisons "good" and "poor" SRH groups were defined by the median score on the SRH item.
Results: EOCSs with "poor SRH" had higher level of somatic symptoms, anxiety, depression and
fatigue than those with "good SRH" (p < .001). In multivariate analyses somatic symptoms, age and
fatigue, were significantly associated with the SRH score in EOCSs, but not the cancer-related
variables (FIGO stage, recurrence in < 6 months or chemotherapy ever). The model explained 70%
of the variance in SRH in linear and 77% in logistic regression analyses. The distribution of the SRH
scores in EOCSs did not differ significantly from that of normative controls; however a higher
proportion of controls recorded a high SRH score.
Conclusion: SRH is strongly related to common somatic complaints, impairment and fatigue but
not to cancer-related variables. A single question concerning SRH last week might be a quick
screening method for collecting important information on symptoms in EOCSs, in addition to
cancer – related questions.
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Background
Due to successful multimodal treatment the number of
women who survive epithelial ovarian cancer has
increased over the last decades. The 5-year survival rate is
45% in Norway, ranging between > 80% in stage I of the
International Federation of Gynecology and Obstetrics
(FIGO) classification to < 20% in FIGO stage IV [1,2]. The
age-adjusted incidence rate of ovarian cancer is 14 per
100,000 women yearly in the United States and 11.8 per
100,000 women in Norway. Bilateral- oophorectomy
(BO) is the primary treatment of epithelial ovarian cancer
combined with chemotherapy dependent on the FIGO
stage. [1,2], however, the majority experience several
relapses and are repeatedly treated with chemotherapy.
Several studies have shown that epithelial ovarian cancer
survivors (EOCSs) have significantly higher levels of
somatic and mental symptoms as well as fatigue com-
pared to women of the general population [3-6]. Stewart
et al. [3] reported that among 200 EOCSs without evi-
dence of disease for two years, 98% regarded their health
as good or excellent, though 54% had current pain or dis-
comfort. We have previously shown that compared to
controls, EOCSs > 18 months after primary treatment had
significantly more chronic fatigue, somatic and mental
morbidity, somatic complaints, use of medications and
more frequently used health care services than popula-
tion-based controls [6]. After treatment, EOCSs will
repeatedly consult their gynaecologists and their regular
general practitioners (GPs), who will assess the EOCSs'
performance and health status by multiple questions in
addition to physical examinations and laboratory tests.
On the other hand, a single statement about self-rated
health (SRH) allows the patients to express various
aspects of their health in a global statement. If considered
as "poor", more focused follow-up questions may be
raised, identifying symptoms which may be accessible for
therapeutic intervention. If SRH is stated as "good", no
further investigation is needed at the moment [7,8]. There
is a widespread consensus that a simple, global SRH ques-
tions may provide a useful summary of the patients' over-
all health status, and SRH has thus been considered as an
important measure of treatment outcome [7-14]. A fre-
quently used measure of SRH is a single question asking
patients to rate their overall health on a scale from excel-
lent to very poor, and there are many alternative phrasings
of such a global question [7-14]. Two questions of the
European Organization and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ C-30)
[15,16] have been used in various SRH studies: item #29
"How would you evaluate your overall health during the
past week?" and item #30:"How you rate your overall
quality of life during the last week". Both items are scored
on 7 point Liker scales, and the responses to these two
items are highly correlated. The literature, however, has
shown that overall health relates principally to somatic
problems, while quality of life encompasses mental
health to a greater extent [7,8].
Butt et al. [9] found single-item screening questions to be
quite effective for fatigue, pain, distress and anorexia in
ambulatory cancer practice with a mixed sample of cancer
patients. Also Rohrer et al. [17] showed in their cross sec-
tional study of 1,183 patients in five community clinics
that the use of a single – item measure of SRH proved to
have clinical value in primary care and helpful to identify
a number of somatic, metal and quality of life symptoms.
Shadbolt et al. [10] reported that SRH responses were
valid, reliable and responsive to objective change of
health in patients with advanced non-gynecological can-
cer. Al-Windy et al. [11] investigated SRH in a general
population based sample of 470 adult persons of multi-
ethnic origins who visited a Swedish Health Care Centre.
On the basis of SRH the authors grouped the persons into
a poor and a good health group, and found SRH helpful
to identify the 46% of the patients who had a significant
number of symptoms. Eriksson et al. [12] in a random
sample of 8,200 Swedish persons compared three differ-
ent SRH questions in order to find the best question meas-
uring lifestyle, psycho-social, mental and physical health
and found this a useful method. The results imply that the
different measure represents parallel assessments of sub-
jective health and that measures without specified
response options are better in younger than older popula-
tion groups.
To our knowledge there are no studies of SRH and its asso-
ciations to somatic and mental morbidity in EOCSs. We
therefore wanted to: 1) Explore the somatic, mental and
lifestyle variables associated with a single question con-
cerning SRH (EORTC) (QLQ C-30) item #29 "How would
you evaluate your overall health during the past week?"
for therapeutic use in a clinical setting. 2) Explore to what
extent the SRH score of EOCS differ from those of age-
matched women in the general population (NORM).
Methods
Patient selection
The EOCSs were 20–70 years at survey with > 18 months
survival since diagnosis. They had been treated according
to protocols for FIGO stage I-III epithelial ovarian cancer
(EOC) at the The Norwegian Radium Hospital [18]. In
order to get a sufficiently powered sample size, we had to
include cases back to 1979. The inclusion criteria were ful-
filled by 297 EOCSs who were alive by September 2004,
and who received a mailed questionnaire. Ten cases were
subsequently excluded after revision of histology, leaving
an eligible sample of 287 EOCSs. A total of 184/189
(97%) EOCSs returned the questionnaire with valid rating
concerning SRH, and had basic anthropometric measuresBMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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and blood samples taken at their regular general practi-
tioners (GPs). One reminder was sent to non-responders
after four weeks.
Treatment principles
All EOCSs had primary surgery with BO, and the majority
also had hysterectomy, omentectomy and maximum
debulking. Primary treatment was done according to
established protocols, as either surgery only, or combined
with subsequent chemotherapy depending on FIGO
stage, histology and ploidy [19].
Platinum-based chemotherapy represented the most fre-
quent systemic treatment. Paclitaxel was incorporated
into the combination chemotherapy in the 1990-ies [18].
The majority of EOCSs received combined carboplatin
and taxol as first line treatment, and nine patients got cis-
platin monotherapy. Relapses were treated with various
types of chemotherapy administered as combinations or
mono-therapy. Among the drugs used were paclitaxel, car-
boplatin, gemcitabine and tamoxifen, and four EOCSs
also had local radiotherapy.
Measurements
EORTC QLQ-C30
The EORTC QLQ-C30 [15] consists of 30 items compris-
ing five functional scales, an overall Global health scale/
QOL scale, three symptom scales, and six single symptom
items. The scores are transformed to 0 – 100 scales: on the
functional scale higher scores represent better function-
ing, while on the symptom scale higher scores mean more
severe symptoms. In this study the presence of somatic
complaints was defined by the median scores (for nausea
and pain a score ≥ 16.67, for dyspnoea, insomnia, consti-
pation, lack of appetite and diarrhoea a score ≥ 33.33).
Item # 29 had seven score alternatives and was considered
to reflect SRH. We transformed the 1 to 7 response score
to 0 to 100 and used the median score (66.67) to separate
the EOCSs into a "poor SRH" and a"good SRH" group.
The correlation between item #29 and #30 was r = 0.83
with 69% explained variance in our EOCSs sample.
As EORTC QLQ-C30 has been psychometrically validated
cross-culturally, all scales and single items have been
tested according to standards for reliability [16]. The inter-
nal consistencies of the functioning scales were: physical
α = .76, role α = .87, emotional α = .89, cognitive α = .72,
social α = .87 and overall QoL/Global health α = .90.
The Hospital Anxiety and Depression Scale (HADS)
The HADS [19] consists of 14 items, 7 on the depression
subscale (HADS-D) and 7 on the anxiety subscale (HADS-
A). Each item is scored on a four-point scale from 0 (not
present) to 3 (considerable), and the item scores are sum-
marized for each scale, giving HADS-D and HADS-A
scores. Based on the literature, cases of HADS-defined
anxiety disorder or depression were defined by a score of
≥ 8 on HADS-A or HADS-D, respectively. Internal consist-
ency of the anxiety subscale was α = .88, and of depression
α = .84 in the EOCSs sample.
The Fatigue Questionnaire (FQ) consists of a total of 13
items, where 11 assess the presence and intensity of
fatigue symptoms [20]. Seven items assess Physical
Fatigue and four assess Mental Fatigue. Summarized they
represent the Total Fatigue score. Based on Total Fatigue
score and duration of fatigue ≥ 6 months, caseness of
Chronic Fatigue (CF) are identified. Internal consistency
was for physical fatigue α = .92, mental fatigue α = .68, and
total fatigue α = .89 in the EOCSs sample.
The Body Image Scale (BIS) is a 10-items self-rating-scale
developed to assess changes of the body image in cancer
patients [21]. The BIS focuses on how EOCSs feel about
their appearance during the past week and on changes in
appearance due to her cancer and/or treatment. Each item
is scored on a four point Likert scale: from 'not at all' (0)
to 'very much very' (3). Increasing BIS score represents
poorer body image. The internal consistency was α = .91
of the BIS in the EOCSs sample.
The Intimate Bond Measure (IBM) is a 24-item self-rating
scale measuring experienced care and control from her
partner in the patient's current relationship [22]. Both
care and control are assessed with 12 items. Each item is
scored on a four point Likert scale from 'not at all' (0) to
'very true' (3). Higher values mean more care or control.
Among the EOCSs in paired relations the internal consist-
ency for care was α = .96 and for control α = .92.
The Menopause-Specific Quality of Life Questionnaire(M-
QOL) is a 29 items questionnaire covering the vasomotor,
physical, psychosocial and sexual menopause-related
domains [23]. The M-QOL was included since has been
shown that menopausal symptoms can be present for a
long time in EOCSs [24]. Each item is first scored as
present or not, and if present a seven point scale of sever-
ity from 'not at all bothered' (0) to 'extremely bothered'
(6) is filled in. In EOCSs the internal consistency for phys-
ical α = .74, psychosocial α = .61 vasomotor, α = .79 and
sexual α = .46. Due to the low internal consistency the sex-
ual domain was excluded from the analyses.
The Sexual Activity Questionnaire (SAQ) consists of three
sections covering: 1) Relation status, 2) Reasons for sexual
inactivity; and 3) Sexual functioning (SAQ-F) [25,26]. The
SAQ-F has a time frame of last month, and consists of 10
items with three subscales: sexual pleasure (7 items), sex-
ual discomfort (2 items) and change in sexual habit (1BMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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item). Sexual pleasure and discomfort are rated on a four-
point Likert scale from 'not at all' (0) to 'very much' (3).
An increasing score means more pleasure and more dis-
comfort, respectively. In the sexually active EOCSs the
internal consistency for SAQ-pleasure was α = .88 and α =
.78 for SAQ-discomfort.
Education was categorized into three levels based on the
number of completed school years (≤  10 years, 11–12
years, > 12 years). Paired relation described those married
or cohabiting. Having paid work was defined as income
from employment or independent business. Level of phys-
ical activity was dichotomized into "minimal", or "moder-
ate or more" according to Thorsen et al. [27]. Physical
impairment and mental impairment were defined as signifi-
cant impairment in daily life for more than one year due
to disease, injury or symptoms.
All co-morbid conditions were self-reported by responses to
the general formulation: "Have your doctor ever said that
you suffer from...?" The self-reported diagnoses were not
validated by their regular GPs or hospital records. Treated
hypertension was defined by current use of an antihyper-
tensive drug, while current hypertension was defined by a
blood pressure ≥ 140/90 mm Hg. Hormone replacement
therapy  (HRT) was reported as current use of sex hor-
mones, while analgesic and psychotropic medication was
reported as regular use last year. Musculo-skeletal diseases
(osteoporosis, fibromyalgia, arthrosis, or other long-
standing musculo-skeletal diseases) were defined as a
diagnosis given by their GPs. Daily smoking concerned cur-
rent consumption of any number of cigarettes.
A clinical Prognostic Index in EOCSs had been con-
structed by our group [6,28] based on scoring of estab-
lished prognostic factors: age at diagnosis, FIGO stage,
relapse within 6 months, modalities of primary treatment
and duration of follow-up time. Presence of prognostic
factors was scored as 1, and absence scored as 0, accord-
ingly: age at diagnosis (≥ 50 years = 1, < 50 = 0); duration
of follow-up (< 5 years = 1, ≥ 5 years = 0); FIGO stage
(stage III = 1, stage I - II = 0); relapse within 6 months (Yes
= 1, No = 0); and primary treatment modality (Surgery +
post-operative chemotherapy = 1, surgery only = 0). The
scores were added-up to an index sum score, and the
EOCSs were allocated to a worst (score 4–5), medium
(score 2–3), or best prognosis (score 0–1) group.
The NORM sample
Normative data for the EORTC QLQ-C30 was obtained by
the Cancer Clinic in 2004 [29]. Using public address lists,
an anonymous age-representative sample of 3,500 Nor-
wegian female population aged 20 to 79 years received a
questionnaire with these instruments. Of the respond-
ents, 1,267 (41%) were in the 30–71 years age range of the
EOCSs, without cancer, and had completed the EORTC
QLQ-C30. We randomly selected three controls for each
EOCSs based on their distribution in 5-year age-groups
from 30 to 75 years (NORM).
Statistical analysis
Continuous data were analyzed by independent sample t-
tests and categorical data with Pearson's χ2 test. 95% con-
fidence intervals (95%CI) were included as appropriate.
Non-parametric tests were applied for skewed distribu-
tions. Internal consistency of a domain/subscale was
examined with Cronbach's coefficient alpha. Statistically
significant findings on continuous variables and on 2 × 2
contingency tables were also calculated as effect sizes
(ESs) and values ≥ .40 were considered as clinically signif-
icant [30,31]. Relevant data were entered as independent
variables in a stepwise hierarchical linear regression anal-
ysis with the SRH score as dependent variable. The
strength of the associations was expressed as standardized
final beta values with all steps in the model, and by
explained variance (R2) and by change in explained vari-
ance (R2-change) for each step. The same procedure was
done with the dichotomized SRH score using logistic
regression analyses, however the strength of association
were expressed as odds ratios (ORs) with 95% confidence
intervals (95%CI).
The level of significance was set at p < .05 and all tests were
two-tailed.
Ethics
The study was approved by the Regional Ethics Review
Board of South-Norway, and the Norwegian Data Inspec-
torate. All EOCSs provided written informed consent.
Results
Attrition analysis
An attrition analysis of the total number of EOCSs
respondents (N = 189) and non-respondents (N = 98)
showed that except for longer time since primary treat-
ment among the respondent (mean 6.3 versus 4.4 years, p
= .003, ES = .35), no significant differences in other clini-
cal variables were observed. (Data not shown).
Clinical characteristics of the EOCSs
SRH last week was rated by 184 of 189 responding EOCSs
(97%). Among these 184 EOCSs the median age at diag-
nosis was 52 years (range 23–68 years), median age at sur-
vey 59 years (range 31–71 years) and median follow-up
time 4 years (range 2–27 years). The FIGO stage distribu-
tion was: stage I 42%, stage II 18% and stage III 40%.
Thirty-three percent of EOCSs had surgery only as primary
treatment, while 67% also got chemotherapy. Using a five
years limit since primary treatment, 44% were considered
as long-term and 56% as short-term survivors. RelapseBMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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ever was observed in 31% of EOCSs. Sixty-five per cent
had < 13 years of basic education, 57% had paid work,
and 42% were pensioned, unemployed or on social sup-
port, and 75% were in a paired relation. (Table 1).
Comparison within the EOCSs group
"Good SRH" and "poor SRH" – demographic, cancer-related and 
somatic variables
According to the definition, 89 (48%) (95%CI 41–57%)
EOCSs had"good SRH" and 95 (52%) (95% CI 44–59%)
had"poor SRH". Mean age at survey was significantly
lower in the patients with"poor SRH" (ES = .37), but no
significant differences were observed for other demo-
graphic or for cancer-related variables such as FIGO stage,
recurrence in < 6 months, chemotherapy ever, follow-up
time or prognostic index. (Table 1).
Somatic complaints and physical and mental impairment
were significantly more often reported in the "poor SRH"
group compared to the "good SRH" group, and all differ-
ences except for diarrhoea had ES > .40, indicating clinical
significance (Table 2). Both use of daily medication and
use of analgesic and psychotropic medication last year
were significantly more common in EOCSs with "poor
SRH" compared to those with "good" SRH (ES = .46). The
prevalence of somatic diseases did not differ significantly
between the groups with "poor" and "good" SRH (Table
2).
"Good SRH" and"poor SRH" – mental distress, sexual function, 
intimate relations, fatigue and quality of life
Compared to the "good SRH" group, the "poor SRH"
group had significantly higher level of anxiety and depres-
sion, poorer body image, and higher levels of physical,
mental and total fatigue, as well as lower M-QoL scores on
the physical, psychosocial and sexual domains. All these
differences were clinically significant (Table 3). A higher
proportion of women with "good SRH" was sexually
active (p < .001), and they scored higher on sexual pleas-
ure (ES = .50) than those with "poor SRH". No significant
differences were observed concerning sexual discomfort
or current use of HRT (Table 3).
Stepwise hierarchical linear and logistic regression analyses
Relevant independent variables were grouped and entered
in a stepwise hierarchical linear and logistic regression
analysis to examine their association with the dimen-
sional and categorical SRH score, respectively. Their asso-
ciation with the dimensional SRH and with the
categorical SRH score is shown in Table 4. By using
dimensional SRH the somatic complaints contributed
mostly (39%) to the explained variance of the SRH score
(p < .001). The demographic variables explained 19% of
the variance in SRH (p < .001), physical or mental impair-
ment contributed 3% (p < .001) and anxiety and fatigue
contributed 3% (p = 0.01). Cancer-related variables
(FIGO stage, relapse < 6 months, chemotherapy), use of
medication, life style and menopausal variables did not
make any significant contributions to the explained vari-
ance of the SRH score. In total the eight step model
explained 70% of the variance in SRH (Table 4).
By using stepwise logistic regression analyses of variables
associated with the categorical SRH score, somatic com-
plains contributed 46% of the explained variance of the
SRH score (p < .001). The demographic variables
explained 8% of the variance in SRH (p < .05), physical or
mental impairment contributed 7% (p = .001) and anxi-
ety and fatigue contributed 3% (p = .001). Cancer-related
variables (FIGO stage, relapse < 6 months, chemother-
apy), use of medication, life style and menopausal varia-
Table 1: Demographic and cancer-related characteristics of 
EOCSs in the "good" and the "poor" SRH groups.
Variables Good SRH
(N = 89)
Poor SRH
(N = 95)
PE S a
Mean (SD) Mean (SD)
Age at diagnosis 52.7 (9.2) 50.2 (9.2) .07
Age at survey 59.3 (8.5) 56.2 (8.3) .02 .37
Follow up timeb 6.6 (5.9) 6.0 (6.1) .54
N (%) N (%)
Level of education .62
< 10 years 23 (26) 25 (27)
11–12 years 38 (43) 33 (36)
> 12 years 28 (31) 34 (37)
Employment status .06
Paid work 58 (65) 49 (52)
Unemployed/pensioned 31 (35) 46 (48)
FIGO stage .60
I 40 (45) 38 (40)
II 13 (15) 19 (20)
III 36 (40) 38 (40)
Recurrence in < 6 month 25 (28) 33 (35) .33
Chemotherapy + surgery 62 65) 62 (70) .35
Surgery only 32 (36) 28 (30)
Prognostic index .35
Good 26 (29) 26 (37)
Medium 49 (55) 46 (48)
Poor 14 (16) 23 (24)
On-treatment last 6 month 25 (28) 33 (35) .33
a Effect size. b Non-parametric testBMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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bles did not make any significant contributions to the
explained variance of the categorical SRH score. In total
the eight step model explained 77% of the variance in
SRH.
Comparison of EOCSs and NORMs
No significant differences were found in level of educa-
tion, paired relation, use of analgesics, psychotropics,
HRT or antihypertensive drugs between EOCSs and
NORM (data not shown). No significant differences in the
overall distribution of the SRH scores between the EOCSs
and NORM were observed, however a higher proportion
of controls recorded a SRH score of 100 (p < .02) (Figure
1).
Discussion
Main findings
Somatic complaints (nausea, pain, dyspnoea, insomnia,
lack of appetite, constipation), mental distress, fatigue,
body image and menopause-related QoL, were signifi-
cantly more common among EOCSs with "poor" rather
than "good" SRH when using the median score to separate
the two groups. Item #29 of the EORTC QLQ C-30 was
thus strongly associated with common somatic com-
plaints, which explained 39% of the variance using
Table 2: Somatic morbidity of EOCSs in the "good" and the "poor" SRH groups.
Variables Good SRH
(N = 89)
Poor SRH
(N = 95)
PE S a
N (%) N (%)
Infarction, angina, stroke 16 (18) 23 (24) .35
Hypertension > 140/90
Treated and untreated 31 (44) 31 (42) .83
On antihypertensive medication 13 (15) 19 (20) .34
Diabetes 1 (1) 4 (4) .20
BMI > 28 21 (25) 24 (27) .74
Hyperthyroidism/hypothyroidism 11 (12) 13 (14) .79
Musculo-skeletal diseases 33 (37) 44 (46) .20
Aches and pain > 3 months/last year 44 (49) 64 (67) .01 .40
EORTC somatic complaints
Nausea 1 (1) 17 (22) < .001 .77
Pain 11 (19) 67 (81) < .001 1.02
Dyspnoea 21 (23) 49 (52) < .001 .93
Insomnia 37 (42) 75 (79) < .001 .60
Lack of appetite 5 (6) 33 (35) < .001 .77
Constipation 26 (29) 50 (53) .002 .43
Diarrhoea 25 (28) 42 (45) .022 .36
Physical impairment 7 (8) 46 (52) < .001 1.10
Mental impairment 4 (5) 22 (25) < .001 .70
Physical activity .55
Minimal exercise 23 (26) 20 (22)
Moderate or more exercises 66 (74) 74 (78)
Medication last year
Daily use of medication 57 (64) 84 (91) < .001 .46
Use of analgetics 6 (7) 35 (37) < .001 .77
Use of psychotropics 13 (15) 47 (50) < .001 .78
a Effect size.BMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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dimensional SRH and 46% using categorical SRH, but
also with age, physical impairment and mental distress
which explained a small but significant association. The
7% difference in explained variance using dimensional or
categorical SRH and the different significance of pain,
physical symptoms and prior use of psychotropic medica-
ments is important and interesting, but difficult to
explain. The main interpretation of both models show a
significant and important contribution for symptoms
which appears to have clinical implications. The relevance
of this single item in EOCSs may be supported by the fact
that these symptoms are known to be frequently present
among EOCSs, and are all conditions which may be acces-
sible for therapeutic interventions. Interestingly the can-
cer-related variables (FIGO stage, recurrence within 6
months, chemotherapy ever), use of medication, life style
and menopausal variables did not make any significant
contributions to the explained variance of the SRH score
in EOCSs used both as dimensional and categorical
dependent variable. We did not observe any significant
differences in the overall distribution of the SRH scores
between the EOCSs and NORM, however, it was a differ-
ence in the highest score level, as a significantly higher
proportion of controls recorded a SRH score of 100 (Fig-
ure 1). This indicates an important difference, indeed.
Comparison with other studies of SRH
SRH has not been studied in EOCSs previously. The use of
a single – item measure of SRH has proven to have clinical
value in primary care [8,12,17], as we also confirmed in
our study. In accordance to the studies of Butt et al. [8]
and Shadbolt et al. [12] in mixed samples of cancer
patients, we found that a single question concerning SRH
could be helpful for health care professionals to screen for
especially physical problems in EOCSs, but also fatigue
and mental distress. Compared to studies of general pop-
ulation samples by Al-Windi [9] and Eriksson et al. [10],
we found that SRH also was associated with demographic
and multiple somatic and mental symptoms.
Clinical implications
SRH allows the respondents in a summarized form to
express different aspects of their health which they con-
sider relevant, and some aspects of which may be accessi-
ble for therapeutic intervention [7,8]. Somatic complaints
showed the strongest associations with the SRH score. To
Table 3: Mental morbidity, intimate relations, sexuality, body image, fatigue and menopausal-related quality of life of EOCSs in the 
"good" and the "poor" SRH groups
Good SRH
(N = 89)
Poor SRH
(N = 95)
PE S a
HADSb
Anxiety level, mean (SD) 3.8 (3.2) 7.1 (3.8) < .001 .51
Depression level, mean (SD) 1.7 (1.8) 4.4 (3.7) < .001 .92
Caseness of anxiety, N (%) 9 (10) 45 (47) < .001 .80
Caseness of depression, N (%) 1 (1) 18 (19) < .001 .70
Fatigue, mean (SD)
Physical level 7.1 (2.7) 11.3 (4.1) < .001 1.20
Mental level 4.3 (1.4) 5.4 (1.9) < .001 .66
Total level 11.4 (3.7) 16.7 (5.3) < .001 1.15
Caseness of chronic fatigue, N (%) 4 (5) 37 (39) < .001 .95
Body Image Scale, mean (SD) b 3.3 (4.2) 7.1 (6.6) < .001 .68
Menopause-specific QoL, mean (SD)
Vasomotorb 2.4 (1.6) 2.8 (1.9) .17
Psychosocial 2.2 (1.2) 3.7 (1.5) < .001 1.10
Physical 2.3 (0.8) 3.6 (1.2) < .001 1.27
Current hormone replacement N (%) 25 (28) 28 (30) .84
Paired relation, N (%) 69 (77) 68 (73) .49
Currently sexually active, N (%) 58 (61) 33 (35) < .001 .53
N= 70 N = 73
Intimate Bond Measure, mean (SD)
Partners' care 29.0 (7.0) 25.7 (9.6) .002 .39
Partners' control b 5.1 (6.8) 6.7 (7.2) .094
N = 54 N = 33
Sexually active, mean (SD)
Pleasureb 8.9 (6.7) 5.8 (5.6) .004 .50
Discomfortb 3.8 (1.8) 3.7 (1.9) .88
aEffect size. bNon-parametric testBMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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Table 4: Stepwise hierarchical linear and logistic regression analyses of variables associated to self rated health (SRH) score.
Independent variables Dimensional SRH Categorical SRH
Beta P OR 95%CI P
Step 1. Demography
Age at diagnosis 0.14 0.03 0.95 0.88–1.03 0.24
Civil status (Paired = reference) 0.05 0.34 1.00 0.13–7.43 0.99
Level of education (> 12 years = ref) 0.06 0.55 2.55 0.45–14.51 0.29
Work status (active reference) -0.12 0.06 0.65 0.11–3.89 0.64
Explained variance (R2) 0.187 < 0.001 0.084 0.055
Step 2. Cancer related variables
FIGO stage (I+II reference) 0.09 0.17 0.23 0.05–1.10 0.07
Relapse < 6 months (no = ref) -0.05 0.39 0.53 0.09–3.15 0.49
Chemotherapy ever (no = ref) -0.04 0.52 2.65 0.45–15.81 0.28
Explained variance (R2) 0.218 0.15 0.109 0.424
Increase of variance (R2-change) 0.032 0.025
Step 3. Somatic complaints
Nausea -0.16 0.02 1.08 0.99–1.17 0.10
Pain -0.15 0.05 1.05 1.01–1.09 0.01
Dyspnoe -0.13 0.06 1.01 0.98–1.04 0.56
Insomnia -0.08 0.32 1.01 0.96–1.02 0.52
Lack of appetite -0.04 0.58 0.99 0.98–1.07 0.40
Constipation -0.09 0.16 1.02 0.99–1.05 0.20
Diarrhea -0.02 0.69 1.00 0.97–1.04 0.87
Explained variance (R2) 0.606 < 0.001 0.571 < 0.001
Increase of variance (R2-change) 0.387 0.462
Step 4. Impairment
Physical impairment -0.10 0.16 11.73 1.28–108.02 0.03
Mental impairment -0.08 0.22 0.53 0.05–5.39 0.57
Explained variance (R2) 0.639 0.004 0.645 0.001
Increase of variance (R2-change) 0.033 0.074
Step 5. Medication last year
Daily use of medication -0.09 0.12 2.66 0.38–18.60 0.33
Use of analgetics 0.01 0.90 2.84 0.33–24.57 0.34
Use of psychotropics -0.05 0.50 13.78 2.07–91.85 0.01
Explained variance (R2) 0.653 0.17 0.717 0.001
Increase of variance (R2-change) 0.014 0.072
Step 6. Anxiety and fatigue
HADS-Anxiety -0.07 0.35 1.07 0.85–1.35 0.58
FQ Total fatigue -0.16 0.02 1.24 1.05–1.47 0.01
Explained variance (R2) 0.682 0.006 0.759 0.007
Increase of variance (R2-change) 0.029 0.042
Step 7. Life style
Body Image Scale score -0.12 0.07 1.09 0.92–1.30 0.32
BMI 0.01 0.83 0.97 0.80–1.18 0.79
Physical activity (moderate or more = reference) -0.11 0.04 0.84 0.16–4.42 0.84
Smoking (no = reference) 0.04 0.54 0.67 0.08–5.49 0.71
Explained variance (R2) 0.703 0.09 0.766 0.806
Increase of variance (R2-change) 0.021 0.007
Step 8. Menopausal QoL
Vasomotor score -0.08 0.14 1.26 0.78–2.03 0.35
Explained variance (R2) 0.709 0.14 0.769 0.34
Increase of variance (R2-change) 0.006 0.003BMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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ask for SRH last week may be a quick and useful question
to screen for symptoms in EOCSs which thus can be rec-
ognized by health care professionals. Somatic complaints,
but also impairment and fatigue, are frequently present
among EOCSs whether they are heavily treated or not.
They may experience constipation or insomnia associated
to surgical menopause or worry; some may have nausea
and bowel dysfunction due to bowel surgery as part of pri-
mary or relapse surgery. Those with stabile disease or pro-
gression often experience various somatic symptoms due
to peritoneal and bowel cancer spread, side effects of med-
ication, or related to repeated courses of chemotherapy
over months. Opportunities for treatment may then be
easily evaluated by the gynaecologist or the regular GPs
and provide basis for development of new strategies for
better medical follow-up treatment of EOCSs on somatic
and mental morbidity, fatigue, sexual problems, and
quality of life.
Strength and limitation
The 66% respondent rate in EOCSs is considered as quite
good since many women were treated many years ago and
some of the questionnaires contained sensitive familial
and sexual issues. We have used internationally accepted
instruments that are well validated and showing good
psychometric properties in our study, except for the M-
QOL sexual domain. We also have analyzed attrition data
on the non-respondents. There were only few significant
differences between the responding and non-responding
EOCSs, which indicate that the findings could be valid for
our total sample of EOCSs and more generally.
One limitation of our study is that the EOCSs were treated
over a long time period (29 years), however treatment and
follow-up protocols were considered to be quite similar
during that time period. Furthermore, the phenomenon
of "response shift", explained as how individuals integrate
changes in their health state so that their internal stand-
ards, values, or concepts of quality of life are nearly
unchanged from before, may be considered as a limita-
tion [32], as studies have shown that patients with objec-
tively "poor health" often valued their health status as
almost normal based on response shift [32]. This fact may
also influence the experience of pain and other somatic
complaints [32], and may explain the lack of the overall
differences we found between cases and controls.
The cross- sectional design has its limitation by the
present knowledge about previous health status. The use
of item #29 of the EORTC QLQ-C30 and the median score
as the cut off of a clinical classification for "poor" and
"good" SRH may be open for discussion, compared to the
use of the variable as a continuous measure. However, we
found that a cut-off for "poor" and "good" SRH was useful
to identify those at highest risk of morbidities and com-
plaints and decreased SRH in EOCSs.
Distribution of Q-29 scores in EOCSs and NORM Figure 1
Distribution of Q-29 scores in EOCSs and NORM. Y- axis: Percent of EOCSs and NORM in relation to levels of SRH 
score.BMC Cancer 2009, 9:2 http://www.biomedcentral.com/1471-2407/9/2
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Conclusion
SRH was strongly associated to common somatic com-
plaints, but also to impairment and fatigue, which are
well known symptoms in EOCSs, but not to cancer-
related variables as FIGO stage, recurrence < 6 months or
chemotherapy ever. A single question concerning SRH last
week might be a quick method to screen for symptoms in
EOCSs, some of which may be accessible for therapeutic
interventions and in addition to cancer – related ques-
tions.
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